Articles Archives - Page 177 of 733

MondayMay 22, 2023 11:15 am

Lift Toronto 2023 Conference & Expo: Lifting the Rapidly Expanding Cannabis Industry & Community

Cannabis industry leaders, entrepreneurs, policymakers, service providers and consumers are all invited to attend the Lift Toronto 2023 Conference & Expo to be held at Metro Toronto Convention Centre from June 1-3, 2023. The advocacy-oriented, strategy-focused Lift Cannabis Business Conference (“LCBC”) on June 1st kicks off the three-day event and is dedicated to discussing best practices in evolving cannabis industry topics, brushing up on policy matters, and connecting with industry leaders. The Lift Cannabis Business Conference is an ideal opportunity for those who are serious about thriving in the global cannabis industry; it is the premiere gathering of subject matter…

MondayMay 22, 2023 10:30 am

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Targets Beijing Influence Over Global Rare Earth Industry; Doubles Down on its North American Investment

China currently commands approximately 90% of rare earth metals, alloys, and permanent magnets, along with 85% of the world’s rare earth oxides This dominance has seen Beijing demonstrate a willingness to leverage it in pursuit of political objectives Countries have resorted to looking elsewhere for the supply of rare earths, and Ucore is building to satisfy that demand in North America Its recent announcement of a $75 million investment in CapEx over the next four years reflects the company’s understanding of the North American REE market and the value that the investment will create for its shareholders Ucore Rare Metals…

MondayMay 22, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Human Oral Nicotine Study, Hopes to Facilitate More Satisfying Experience with DehydraTECH(TM)-Processed Oral Nicotine

Lexaria recently reported that dosing of the targeted 36 volunteers in its human clinical oral nicotine study, NIC-H22-1, had been completed The company hopes to demonstrate that its DehydraTECH(TM)-processed nicotine absorbs more quickly and more efficiently into the human bloodstream than leading oral nicotine brands Through previous animal testing, Lexaria showed that DehydraTECH-nicotine was up to 10x to 20x faster in delivering comparable levels of nicotine and delivered up to 6-fold higher levels of nicotine into blood plasma than concentration-matched controls If the findings from the human study replicate a similarly improved performance, Lexaria believes this could facilitate a more…

MondayMay 22, 2023 9:00 am

GeoSolar Technologies Inc. & George Soros Share One Thing in Common – A Desire to Halt Global Warming

George Soros recently warned on the effects of global warming, stating that the potential melting of the Greenland ice sheet could threaten the future of survival GeoSolar Technologies has looked to deliver on the technological advances needed to address climate change, through the development of its proprietary Smart Green(TM) Home system The residential energy solution seeks to harness solar and geothermal energy in a bid to slash household emissions – whilst simultaneously reducing household utility bills Billionaire investor, George Soros is well renowned for being outspoken about causes he is passionate for; most recently, his target has been centered around…

FridayMay 19, 2023 9:45 am

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) Continues to Grow Through Regional Expansion and Cross-Market Opportunities

As a natural byproduct of landfills and animal waste, RNG presents a powerful tool for reducing environmental impact: it helps curb carbon emissions, diverts organic waste from landfills and has the potential to revolutionize transportation Committed to accelerating the shift of the grid to renewable natural gas (“RNG”), EverGen Infrastructure acquires, develops and manages RNG systems that aim to bring sustainable energy from organic waste into the North American gas grid EverGen deploys a growth strategy that is based on a combination of regional expansion that replicates the company’s business model regionally and cross-sector expansion whereby EverGen seeks to capitalize…

FridayMay 19, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pivotal Milestones Concerning DehydraTECH(TM) Technology, Including IND Application Plans

Lexaria's patented DehydraTECH(TM) technology enhances drug bioavailability, making it useful for a wide range of product formats, including pharmaceuticals, neutraceuticals, consumer packaged goods, and over-the-counter pills, capsules, tablets, and oral suspensions The company is currently exploring the potential benefits of DehydraTECH related to several molecules including, purified nicotine, CBD, antiviral drugs, human hormones, and PDE5 inhibitors Lexaria recently announced the completion of its diabetes animal study DIAB-A22-1 with at least three positive outcomes using DehydraTECH-CBD California-based InClin, Inc. has been awarded the contract for clinical research organization services for the expected upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1…

ThursdayMay 18, 2023 10:30 am

Web3 Berlin Set to Host Europe’s Biggest Crypto & NFT Conference in June

Web3 Berlin is set to host an annual event on the 10th and 11th of June at the Estrel Congress Center. The conference promises to be an unforgettable experience where attendees can focus on networking, onboarding, and education about Web3, and most importantly, it aims to be the biggest Crypto & NFT event in Europe. The conference has already established itself as a major event on the Web3 calendar, having signed up more than 80 partners, including leading companies and organizations in the industry, such as Solana, Dash, Ramp, KuCoin, VeChain, Celo or Fantom Foundation. "We are aiming to create…

ThursdayMay 18, 2023 9:45 am

CISO Global Inc. (NASDAQ: CISO) Earns Overweight Rating in Latest Cantor Fitzgerald Equity Research Report

The equity report noted CISO’s triple-digit Q4 growth in several areas “We expect Cerberus to build on its momentum in making headway into larger enterprise customers,” report observes Cybersecurity talent shortage landscape could be “highly favorable” to Cerberus A recent Cantor Fitzgerald equity research report is high on CISO Global (NASDAQ: CISO), formerly Cerberus Cyber Sentinel Corp., a leading provider of global cybersecurity and compliance. Noting that the company is strategically positioned to fill the cybersecurity talent shortage gap, Cantor Research gave CISO an overweight rating and a $2 price target (https://nnw.fm/EP1WX). “Reiterate overweight and moderating our 12-month price target…

ThursdayMay 18, 2023 9:00 am

Electronic Servitor Publication Network Inc. (XESP) Is ‘One to Watch’

In September 2022, XESP announced its new business strategy of providing managed digital engagement services through its DE2 platform In February 2023, XESP named Peter Hager as its President and CEO The company’s digital engagement technology has helped dozens of organizations achieve growth results up to nine-times the industry standard XESP is a market disrupter for B2B companies looking for $10M+ in additive growth per year Electronic Servitor Publication Network (OTCQB: XESP) is a digital engagement company offering a managed service which provides digital activation and engagement solutions to companies that seek to optimize their growth. Its managed service is powered…

WednesdayMay 17, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) Research Collaborators Present Positive Preclinical Data at American Association of Cancer Research 2023 Annual Meeting

Positive preclinical data was presented for the NPRL2 tumor suppressor gene The studies used Genprex’s non-viral ONCOPREX(R) Nanoparticle Delivery System in KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung cancer (“NSCLC”) humanized mouse models Validates ONCOPREX(R) platform’s ability to deliver other tumor suppressor genes to potentially address multiple types of cancer ONCOPREX(R) Nanoparticle Delivery System is the novel non-viral platform being used for the company’s lead drug candidate, REQORSA(R) Immunogene Therapy, initially targeting lung cancer Genprex (NASDAQ: GNPX), A cutting-edge gene therapy company striving to improve the lives of cancer and diabetes patients through the creation of groundbreaking treatments,…

Site Search

Company Search

Category: Articles